SubHero Banner

Vizimpro® (dacomitinib) – New orphan drug approval

September 27, 2018 - Pfizer announced the FDA approval of Vizimpro (dacomitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

Download PDF